Jaguar Health Executes Preferred Stock Conversion

Jaguar Health, Inc. announced the conversion of its Series O Convertible Preferred Stock into common stock. Each preferred share will convert into 3.209 shares of common stock without requiring action from stockholders. This decision stems from a one-time special stock dividend issued earlier in 2026, aimed at rewarding investors and protecting against potential dilution. Stockholders entitled to fractional shares will receive cash instead, based on the June 24 closing price of $2.68 per share.

Jaguar's conversion aligns with its strategic focus on developing crofelemer for rare intestinal diseases. The company plans to demonstrate crofelemer's benefits at the 2026 ESPGHAN Meeting. Jaguar is pursuing FDA approval for crofelemer targeting microvillus inclusion disease, with application plans set for early 2027.

This move highlights Jaguar's efforts to balance investor interests and advance its therapeutic programs, emphasizing its commitment to solving rare gastrointestinal disorders.